Promopharm: 15% Increase in Revenue by the End of September 2025

In the third quarter of 2025, Promopharm recorded a double-digit revenue growth of 15%, amounting to 221.5 million dirhams compared to the same period in 2024. This performance reflects a strong market momentum, driven by the successful launch of new products. Promopharm's debt level saw a significant decrease, dropping from 228 million dirhams on December 31, 2024, to 199 million dirhams by the end of September 2025. This reduction in debt indicates rigorous financial management and effective control of working capital. During the first nine months of 2025, Promopharm made investments totaling 20 million dirhams. These investments primarily focused on enhancing production capacity and developing IT systems.